- Veritas Pharma is unlocking the science underlying medical cannabis
- Clinically profiling select cannabis strains – pharmacologically identifying strains for specific disease conditions
- Entering human clinical studies with valuable IP’s in place
There is growing support for medicinal cannabis. Repeated peer-reviewed studies have demonstrated positive patient responses in a variety of maladies. However, to date, the response has been largely anecdotal, and, unlike rigorous pharmacology, the precise mechanisms and chemical profiles of cannabinoids remain unknown. Through exacting scientific protocols, Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is about to radically change the understanding and applications of this millennia-old medicine.
Led by experienced management and bolstered with veteran academic pharmacologists, anesthetists and chemists, Veritas Pharma is rapidly unlocking the science underlying medical cannabis. The company chemically profiles different marijuana cultivars (specific plant varieties produced in cultivation by selective breeding). The cultivars are then pharmacologically profiled to identify disease-specific strains, and once these stringent protocols are achieved, Veritas performs clinical trials to establish the clinical utility and efficacy of each cultivar.
After exhaustive chemical and animal assays delivered favorable results, Veritas recently announced its research subsidiary, Cannevert Therapeutics Ltd., has signed a letter of intent to initiate the human study of CTL-X, the company’s lead cannabis strain targeting pain (http://cnw.fm/ypBt5). The study will be undertaken at Fundación de Investigación, a highly respected clinical research center with state-of-the-art facilities and in-house bioanalytical laboratory located in San Juan, Puerto Rico. Veritas’s CEO Lui Franciosi stated in part, “It’s important to us to move quickly into this next phase of providing clinical proof of cannabis’ effectiveness….We aim to provide physicians and patients with scientifically tested and clinically proven cannabis therapies targeting pain. In the next year, Veritas’s goal is to have a branded analgesic strain in which its dose and method of administration are standardized to actively compete with over-the-counter analgesics as well as potentially reducing or eliminating opioid use in the acute and chronic pain markets.”
Delivering scientifically tested and clinically proven standardized cannabis therapies is a potential game changer throughout the entire nascent medical cannabis industry. In addition to developing clinically proven effective cannabis strains (cultivars) specific to pain, Veritas is targeting pain, nausea, epilepsy and PTSD. During development of these therapies, the company institutes broad patent protections for its potential blockbuster intellectual properties. Targeting multi-billion dollar global markets, the company’s unique value proposition uses a low-cost research and development model to drive speed-to-market. Veritas intends to license or sell its IP’s to cancer clinics, the insurance industry and pharmaceutical companies.
Anecdotally embraced, the rush into marijuana as medicine has been hamstrung by lack of pharmacologically profiled, scientifically tested, clinically proven therapies. Real medicine requires real science. Veritas Pharma is poised to deliver the requisite real science and indelibly transform medical cannabis therapeutics.
For more information, visit the company’s website at www.VeritasPharmaInc.com
More from CanadianCannabisWire
CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CanadianCannabisWire.com